


Acquisition of NewCo Pharma GmbH

November 25, 2021

Third acquisition in 18 months



NewCo Pharma in a nutshell


NewCo Pharma Company Overview

Mannheim, Germany 200 employees 🔲 Founded in 2014

- Strong foothold in Western and South-Western Germany
- 5 compounding facilities with >200,000 preparations
- Long-term business partner to pharmacies with compounding and support services (invoicing, software, training)
- Focus on oncology and other parenteral therapies
- Strong wholesale business supporting attractive purchasing conditions for PST business

To be integrated mainly into the Patient-Specific Therapies business segment

NewCo Pharma Revenues in €m




MEDIOS PST: Patient-Specific Therapies

Strategic rationale

1	Highly complementary footprint significantly expanding geographical coverage of the German market with capacity to deliver now time-critical drugs to almost any specialized pharmacy in the country
2	PST revenues to immediately triple , with leading position in attractive compounding business for parenteral therapies (infusion, injection)
3	Stronger position to meet current and future trends such as individualization and decentralization of services
4	Significant cross-selling potential , expansion of the segment portfolio, and synergies within the segment thanks to the perfect cultural fit
5	Strong growing and profitable business (EBITDA margin 8.6% in 2020) acquired at an attractive valuation

Leading specialty pharma provider with nationwide market coverage




- **Around 50** specialized Tier 1 partner pharmacies added to Medios network
- Portfolio of compounding preparations extended
- Compounding volume and capacity expanded
- Increased capability to supply any time-critical drug to any specialized pharmacy in Germany



In combination with our unrivalled digital software platform **mediosconnect**, specialized pharmacies and prescribing physicians now have one place to meet all their compounding needs.

5

Major compounding capacity expansion with NewCo Pharma acquisition



- 5 GMP² compounding facilities joining Medios platform
- Located exclusively in Western Germany with high geographical complementarity to Medios existing compounding facilities in Berlin & Cologne
- NewCo Pharma focused on manufacturing cytostatic infusions, parenteral nutrition and eye injections
- Significant remaining capacity available at NewCo Pharma's existing facilities and ready to serve surge in activity from cross-selling
- Medios' **compounding capacity** to significantly increase **immediately**
- Medios to become the undisputed leader in terms of PST-portfolio



PST: Patient-specific Therapies | ¹Acquisition closing expected in Q1 2022; ² GMP: Good Manufacturing Practice; ³Pro-forma = Including Medios and NewCo Pharma

Major operational synergies



- Increased purchasing power as a result of higher volume
- Reduced cost of supply by combining Medios' and NewCo Pharma's diversified sourcing





- "Insourcing" of several corporate services currently outsourced by NewCo Pharma: Finance, HR
- Economies of scale
- Increased revenues through crossselling synergies




New opportunities

- NewCo Pharma approved to work directly with trial centers and sponsors of clinical trials
- Broad product spectrum (e. g. pain therapy) enables further diversification of Medios' portfolio



MEDIOS

Significant cross-selling potential in terms of products / clients





MEDIOS

Medium term outlook – Internationalization and new segments

- M&A strategy to continue, focusing on internationalization and new segment with higher-margin potential
- Accelerate organic and external growth in Patient-Specific Therapies
- Continuing to expand focus on high-margin indications and products

• Leverage medios Connect to expand innovative services offering and increase reach

Transaction summary

Acquisition Target	 100% of NewCo Pharma GmbH, Mannheim Among the leading Patient-Specific Therapies providers in Western and South-Western Germany
Size & Valuation	 €125m Enterprise Value (purchase price could be slightly different depending on the audited closing accounts as of December 31, 2021) 2021 EV/EBITDA multiple: 8 – 9x; depending on NewCo Pharma's final FY 2021 EBITDA
Financing	 ~ 29% of the purchase price (~ €35m¹) to be paid in shares 924,233 newly issued shares subject to a lock-up of 12 months (50%) and 24 months (50%) Remaining purchase price portion to be paid from existing cash and a committed debt financing Alternative financing will be explored
Conditions & Timing	 Closing subject to anti-trust approval NewCo Pharma's management to join Medios Closing expected in Q1 2022

Next steps

- Anti-trust approval
- Fulfillment of closing conditions
- Closing expected early Q1 2022
- Integration of acquired company
- NewCo Pharma management to join Medios
- M&A strategy to be continued

MEDIOS

Contact

Claudia Nickolaus Head of Investor & Public Relations Phone: + 49 30 232 566 800 ir@medios.ag

Disclaimer

contained herein are as up to date as is reasonably possible and are subject to revision in the the Company or information from third party sources, contained in this presentation are based future. None of the Company or its directors, officers, employees or advisors nor any other person makes any representation or warranty, express or implied as to, and no reliance should be placed on, the accuracy or completeness of the information contained in this presentation. None of the Company or any of its directors, officers, employees and advisors nor any other person shall have any liability whatsoever for any loss howsoever arising, directly or indirectly, from any use of this presentation. The same applies to information contained in other material made available at the presentation. While all reasonable care has been taken to ensure the facts stated herein are accurate and that the opinions contained herein are fair and reasonable, this presentation is selective in nature and is intended to provide an introduction to, and overview of, the business of the Company. Where any information and statistics are quoted from any external source, such information or statistics should not be interpreted as having been adopted or endorsed by the Company as being accurate.

This presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and /or the industry in which the Company operates Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words »believes«, »expects«, »predicts«, »intends«, »projects«, »plans«, »estimates«, »aims«, »foresees«, »anticipates«, »targets« and similar expressions in English or equivalent expressions in German.

This presentation has been produced by Medios AG (the "Company"). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of on current plans, estimates, assumptions and projections and involve uncertainties and risks. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecasted developments. No obligation is assumed to update any forwardlooking statements.

> This presentation does not constitute or form a part of, and should not be construed as, an offer or invitation to subscribe for, or purchase, any securities and neither this presentation nor anything contained herein shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

> In particular, this presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares in the Company may not be offered or sold in the United States or to or for the account or benefit of "U.S. persons" (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")) absent registration or an exemption from registration under the Securities Act. The shares in the Company have not been and will not be registered under the Securities Act.

> This presentation speaks as of November 2021. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date.

Acquisition of NewCo Pharma GmbH

November 25, 2021